Salute e Benessere
General Inception acquires Enable Medicine and announces strategic partnership to accelerate drug discovery with AI-led generative biological search
Enable Medicine harnesses the revolutionary capabilities of AI to guide novel insights into biology and medicine. The platform unlocks the power of generative biological search, which uses cutting-edge AI models to search maps of disease for novel drug targets and indications. The approach prioritizes indexing high quality multimodal cellular data to enable the research community and pharmaceutical industry to quickly answer complex questions about disease.
Biological data is complex, fragmented and frequently inaccessible, with siloed organization and "single use data" meaning that critical insights may be obscured and groundbreaking therapeutic discovery hindered.
Enable is building the largest, most comprehensive biological atlas to index, integrate, and interrogate vast, multimodal datasets to generate profound, disease-relevant insights and accelerate discovery. By leveraging the computational power of generative AI to search these atlases, answers to previously unanswerable questions can be unlocked.
The two companies first collaborated in 2023, when they established Ennovate Pharma, which develops precision therapeutics for autoimmune and inflammatory diseases by leveraging biological atlases to identify, stratify and understand why certain patients do not respond to current therapies.
Using Enable's data platform and AI analysis tools, they revealed vital clinical insights about why some patients with certain autoimmune diseases fail to respond to standard-of-care treatments. After 18 months, they are addressing refractory and non-responder populations in autoimmune disease and have identified and validated several highly promising targets.
:
General Inception and Enable Medicine are now actively seeking data partnerships with healthcare providers and data repositories to utilize their joint approach to develop better drugs and patient treatment strategies.
General Inception (GI) is pioneering company creation as an Igniter company. General Inception partners with extraordinary scientific founders at the inception of their journey to efficiently translate their groundbreaking innovations into transformational companies that address humanity's grand challenges. As a business co-founder, GI brings together domain and functional expertise, executive talent, infrastructure and development resources, and capital to ignite, nurture and scale the company journey. GI is backed by leading venture capital firms Genoa Ventures, Hughes Ventures, Northpond Ventures, OMX Ventures, Paladin Capital Group, and Vertical Venture Partners.
For more information, please visit https://www.generalinception.com/.
At Enable Medicine, our mission is to organize the world's biological data and make it searchable to generate profound new insights into health and disease. We are building the largest and most comprehensive atlas of human biology to index, interconnect and interrogate diverse data inputs from billions of cells and across thousands of patient data sets. On the Enable Medicine platform, scientists use the computational power of AI to search these atlases and unlock answers to previously unanswerable questions. Together, we empower those bringing the next generation of diagnostics and therapeutics forward to deliver better patient outcomes. To accelerate your discoveries with AI-powered biological search on the Enable Medicine Platform, visit https://www.enablemedicine.com.
View original content:https://www.prnewswire.co.uk/news-releases/general-inception-acquires-enable-medicine-and-announces-strategic-partnership-to-accelerate-drug-discovery-with-ai-led-generative-biological-search-302329526.html